Nurix Therapeutics climbs after blood cancer drug trial data
ReutersDec 8, 2025 2:07 PM
Shares of drug developer Nurix Therapeutics NRIX.O jump 19.6% to $21.63 premarket
NRIX said 75% of patients demonstrated objective response rate in early-stage trial for blood cancer drug Bexobrutideg (NX-5948), with mostly mild side effects
Drug is aimed at degrading BTK, a protein that drives the disease
NRIX set to open at its highest after a year if current gains hold
Stock down nearly 4% YTD, up to last close
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Tradingkey
Related Articles
TradingKey 2025 Markets Recap & Outlook | Bitcoin Price Repeatedly Hits New Highs, 2026 Can BTC Write Another Legend?
Multiple tailwinds in 2025 propelled Bitcoin to new highs, but many of these positives have already been priced in. In 2026, Bitcoin faces challenges such as liquidity tightening, as well as regulatory and monetary policy uncertainties. Wall Street is divided on Bitcoin's future outlook, with targetTradingKey
8 hours ago
TradingKey 2025 Markets Recap & Outlook | Global Central Banks 2026 amid Post‑Easing Recovery and Diverging Paths
TradingKey - In 2025, major global central banks will largely maintain an accommodative stance, but the policy pace will decelerate notably. As the easing cycle draws to a close, how will global monetary policy evolve?TradingKey
Thu, Dec 25
Ripple Price Prediction: Why Is XRP Price Falling? Can It Rise to $10 in the Future?
XRP has weakened this year due to profit-taking, capital outflows, and its correlation with Bitcoin. Despite support from potential spot ETFs and positive regulatory developments, significant market divergence, liquidity uncertainty, and macroeconomic uncertainty remain high. XRP's price is likely tTradingKey
Wed, Dec 24
Elon Musk’s SpaceX Poised for Record-Breaking IPO: How Can Retail Investors Get In on the Action of Starlink Stock?
TradingKey - Elon Musk's rocket manufacturer SpaceX is expected to launch an IPO in 2026, with a target IPO valuation projected to reach $1.5 trillion. However, prior to its listing, the stock can only be traded in the private market, characterized by low information transparency and high capital baTradingKey
Fri, Dec 19
Tradingkey
